Market closed
Aldeyra Therapeutics/$ALDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aldeyra Therapeutics
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Ticker
$ALDX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
9
Website
ALDX Metrics
BasicAdvanced
$131M
-
-$0.94
1.24
-
Price and volume
Market cap
$131M
Beta
1.24
52-week high
$7.20
52-week low
$1.14
Average daily volume
2.6M
Financial strength
Current ratio
5.595
Quick ratio
5.438
Long term debt to equity
21.125
Total debt to equity
21.552
Interest coverage (TTM)
-31.21%
Management effectiveness
Return on assets (TTM)
-29.71%
Return on equity (TTM)
-58.54%
Valuation
Price to book
1.84
Price to tangible book (TTM)
1.84
Price to free cash flow (TTM)
-3.015
Growth
Earnings per share change (TTM)
47.41%
3-year earnings per share growth (CAGR)
-4.24%
What the Analysts think about ALDX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aldeyra Therapeutics stock.
ALDX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ALDX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ALDX News
AllArticlesVideos
ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors may be able to Recover Losses in Class Action Investigation -- Contact BFA Law (NASDAQ:ALDX)
GlobeNewsWire·10 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
Accesswire·1 day ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation
Accesswire·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aldeyra Therapeutics stock?
Aldeyra Therapeutics (ALDX) has a market cap of $131M as of April 19, 2025.
What is the P/E ratio for Aldeyra Therapeutics stock?
The price to earnings (P/E) ratio for Aldeyra Therapeutics (ALDX) stock is 0 as of April 19, 2025.
Does Aldeyra Therapeutics stock pay dividends?
No, Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Aldeyra Therapeutics dividend payment date?
Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Aldeyra Therapeutics?
Aldeyra Therapeutics (ALDX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.